Related Experiment Video
Updated: Aug 15, 2026
Quantification of Colonic Stem Cell Mutations
Published on: September 25, 2015
Diagnosis and management of G6PD deficiency
1Department of Family Medicine, Martin Army Community Hospital, Fort Benning, Georgia 31905, USA. Jennifer.Frank@se.amedd.army.mil
Insights
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited disorder affecting 400 million people globally. Management focuses on avoiding oxidative stressors like certain foods, drugs, and infections to prevent acute hemolytic anemia.
Area of Science:
- Genetics
- Biochemistry
- Hematology
Background:
- Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most prevalent enzyme deficiency globally.
- This X-linked inherited disorder affects approximately 400 million individuals, presenting with varied clinical manifestations from asymptomatic cases to severe hemolysis.
- The condition is most common in populations of African, Asian, Mediterranean, and Middle-Eastern descent.
Purpose of the Study:
- To summarize the clinical spectrum, genetic basis, diagnostic approaches, and management strategies for Glucose-6-phosphate dehydrogenase deficiency.
- To highlight the importance of identifying and avoiding triggers for hemolytic episodes.
Main Methods:
- Diagnostic testing relies on assessing the conversion of nicotinamide adenine dinucleotide phosphate to its reduced form in erythrocytes, often via a fluorescent spot test.
- Classification systems categorize different gene mutations based on the degree of enzyme deficiency and disease severity.
- Clinical presentation and management strategies are reviewed based on existing literature.
Main Results:
- G6PD deficiency manifests as neonatal hyperbilirubinemia, acute hemolysis, or chronic hemolysis, with severity influenced by genetic mutations and inheritance patterns (homozygous vs. heterozygous).
- Acute hemolysis is triggered by oxidative stressors including infections, certain medications, and fava beans, and is typically self-limiting but may require transfusion in severe cases.
- Neonatal hyperbilirubinemia necessitates interventions like phototherapy or exchange transfusion to prevent kernicterus.
Conclusions:
- Effective management of G6PD deficiency involves strict avoidance of identified oxidative stressors.
- Understanding the genetic heterogeneity is crucial for predicting disease severity and clinical outcomes.
- While common inherited mutations cause widespread deficiency, rare sporadic mutations can lead to uncommon variants like chronic hemolysis.
Abstract:
Glucose-6-phosphate dehydrogenase deficiency, the most common enzyme deficiency worldwide, causes a spectrum of disease including neonatal hyperbilirubinemia, acute hemolysis, and chronic hemolysis. Persons with this condition also may be asymptomatic. This X-linked inherited disorder most commonly affects persons of African, Asian, Mediterranean, or Middle-Eastern descent. Approximately 400 million people are affected worldwide. Homozygotes and heterozygotes can be symptomatic, although the disease typically is more severe in persons who are homozygous for the deficiency. The conversion of nicotinamide adenine dinucleotide phosphate to its reduced form in erythrocytes is the basis of diagnostic testing for the deficiency. This usually is done by fluorescent spot test. Different gene mutations cause different levels of enzyme deficiency, with classes assigned to various degrees of deficiency and disease manifestation. Because acute hemolysis is caused by exposure to an oxidative stressor in the form of an infection, oxidative drug, or fava beans, treatment is geared toward avoidance of these and other stressors. Acute hemolysis is self-limited, but in rare instances it can be severe enough to warrant a blood transfusion. Neonatal hyperbilirubinemia may require treatment with phototherapy or exchange transfusion to prevent kernicterus. The variant that causes chronic hemolysis is uncommon because it is related to sporadic gene mutation rather than the more common inherited gene mutation.
Related Concept Videos
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
01:20Inborn Errors of Metabolism
01:26Rocky Mountain Spotted Fever
01:25Peritoneal Dialysis III: Nursing Management
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
01:22Diabetes Mellitus: Type 2 and Gestational